Connect with us

Hi, what are you looking for?


Jasper Therapeutics Presented Updated Data From Phase 1 Clinical Trial of JSP191

Jasper Therapeutics, Inc., (NASDAQ: JSPR) announced updated efficacy, safety and pharmacokinetic data from its Phase 1 clinical trial of JSP191, in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.

The data readout revealed, in Phase 1b dose expansion study, with 24 patients suffering from myelodysplastic …

Full story available on


Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like